Public health impact of comprehensive hepatitis C screening and treatment in the French baby-boomer population

Abstract

Objective: To estimate the public health impact of comprehensive hepatitis C virus (HCV) screening and access to all-oral, interferon (IFN)-free direct-acting antivirals (DAAs) in the French baby-boomer population ARTICLE HISTORY

Cost‐effectiveness and health‐related outcomes of screening for hepatitis C in Korean population

“…The ICER in this study was much lower than those conducted in the US, Europe and Canada for birth cohort or general population, which showed a range of 15 700~65 749 USD/QALY, even though the prevalence of HCV was similar to Korea. [7][8][9]40 The more favourable ICER in this study could be explained by the lower screening cost caused by the integration strategy into the NHE Program, a lower cost of anti-HCV testing (one-fifth or one-tenth of those in other studies), and a lower cost of drug therapy. However, countries with no pre-existing health examination system may need additional costs such as administrative or training costs for implementing screening.…”

“…All the costs were expressed in US dollars (USD; one USD = 1172.5 won in 2015). We assumed no cost for adverse events of DAA because interferon‐free DAA treatment has few serious adverse effects as in other studies …”

“…We assumed no cost for adverse events of DAA because interferonfree DAA treatment has few serious adverse effects as in other studies. 9,27 Utilities of HCV patients in each health state were obtained from published literature. 8,10,28 Age-specific utilities in the general population were based on the results of EQ 5D in the Korean National Health and Nutrition Examination Survey 2015.…”

“…There have been several studies on the cost‐effectiveness analysis (CEA) of HCV screening for different target populations . Birth cohorts or a one‐time general population screening was mostly cost‐effective in the USA, Europe and Canada, as well as in Egypt where the HCV prevalence is exceptionally high . The cost‐effectiveness of HCV screening is sensitive to the prevalence of asymptomatic HCV infection, the acceptability of the screening and treatment, treatment and care costs and affordability .…”

Screening for hepatitis C at the emergency department: Should babyboomers also be screened in Belgium?

“…In Europe, HCV prevalence varies within different birth cohorts between countries. In France, the new complementary screening strategy consists of one‐time simultaneous HCV, Hepatitis B virus (HBV) and HIV testing in men aged 18‐60 and pregnant women in the first trimester . They did not find an effect of a specific birth cohort, but decided a pragmatic approach was necessary to detect the undiagnosed population.…”